{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T05:17:57Z","timestamp":1781932677709,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.clinthera.2012.06.014","type":"journal-article","created":{"date-parts":[[2012,7,10]],"date-time":"2012-07-10T15:52:05Z","timestamp":1341935525000},"page":"1735-1750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of the Efficacy and Safety Profiles of Two Fixed-Dose Combinations of Antihypertensive Agents, Amlodipine\/Benazepril Versus Valsartan\/Hydrochlorothiazide, in Patients With Type 2 Diabetes Mellitus and Hypertension: A 16-Week, Multicenter, Randomized, Double-Blind, Noninferiority Study"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct01375322","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"I-Te","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jen","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jane","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne Huey-Herng","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.06.014_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.06.014_bib2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1081\/CEH-200032144","article-title":"Current status of hypertension control around the world","volume":"26","author":"Erdine","year":"2004","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.clinthera.2012.06.014_bib3","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2010.650","article-title":"US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008","volume":"303","author":"Egan","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2012.06.014_bib4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1053\/j.ajkd.2009.06.044","article-title":"Hypertension in the developing world: challenges and opportunities","volume":"55","author":"Mittal","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2012.06.014_bib5","first-page":"e21","article-title":"Heart disease and stroke statistics\u20142009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"119","author":"Lloyd-Jones","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2012.06.014_bib6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1559-4564.2006.05513.x","article-title":"Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors","volume":"1","author":"Kabakov","year":"2006","journal-title":"J Cardiometab Syndr"},{"key":"10.1016\/j.clinthera.2012.06.014_bib7","first-page":"237","article-title":"Prevalence of hypertension among diabetic patients and its relation to vascular risk","volume":"5","author":"Fuller","year":"1991","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.clinthera.2012.06.014_bib8","first-page":"703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [published correction appears in BMJ. 1999;318:29]","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2012.06.014_bib9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes: a consensus approach","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2012.06.014_bib10","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1185\/03007995.2010.494462","article-title":"Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives","volume":"26","author":"Yang","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.06.014_bib11","first-page":"S11","article-title":"Standards of medical care in diabetes\u20142011","volume":"34","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.06.014_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11892-009-0081-y","article-title":"Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering","volume":"10","author":"Ismail","year":"2010","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.clinthera.2012.06.014_bib13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0929-6646(10)60120-9","article-title":"Hypertension Committee of the Taiwan Society of Cardiology","volume":"109","author":"Chiang","year":"2010","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.clinthera.2012.06.014_bib14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/bmj.328.7440.634","article-title":"British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary","volume":"328","author":"Williams","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2012.06.014_bib15","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.2146\/ajhp040583","article-title":"Patterns of antihypertensive therapy in new users of angiotensin II-receptor blockers","volume":"62","author":"Young","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2012.06.014_bib16","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2165\/11319460-000000000-00000","article-title":"Valsartan: more than a decade of experience","volume":"69","author":"Black","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.06.014_bib17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.clinthera.2005.07.010","volume":"27","author":"Lacourci\u00e8re","year":"2005","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2012.06.014_bib18","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2165\/00003495-200262130-00015","article-title":"Valsartan\/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension","volume":"62","author":"Wellington","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.06.014_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/14779072.1.3.335","article-title":"Fixed combination therapy of hypertension: focus on valsartan\/hydrochlorothiazide combination (Diovan\/HCT)","volume":"1","author":"Chrysant","year":"2003","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.clinthera.2012.06.014_bib20","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.014_bib21","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.06.014_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","article-title":"Cardiovascular events during differing hypertension therapies in patients with diabetes","volume":"56","author":"Weber","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2012.06.014_bib23","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2008.102","article-title":"Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study","volume":"73","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2012.06.014_bib24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.014_bib25","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"ONTARGET Investigators","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.06.014_bib26","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.014_bib27","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1093\/ndt\/gfq792","article-title":"Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials","volume":"26","author":"Maione","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.06.014_bib28","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2012.06.014_bib29","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jama.295.10.1152","article-title":"Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement","volume":"295","author":"Piaggio","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2012.06.014_bib30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5694\/j.1326-5377.2009.tb02425.x","article-title":"Non-inferiority trials: determining whether alternative treatments are good enough","volume":"190","author":"Scott","year":"2009","journal-title":"Med J Aust"},{"key":"10.1016\/j.clinthera.2012.06.014_bib31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jclinepi.2006.02.007","article-title":"Analysis of covariance in medical research","volume":"59","author":"Van Breukelen","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2012.06.014_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-1-59745-530-5_13","article-title":"Analysis of change","volume":"404","author":"Grady","year":"2007","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.clinthera.2012.06.014_bib33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0197-2456(94)90017-5","article-title":"A comparison of two methods of estimating a common risk difference in a stratified analysis of a multicenter clinical trial","volume":"15","author":"O'Gorman","year":"1994","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clinthera.2012.06.014_bib34","first-page":"15","article-title":"Fisher's exact test: an easy-to-use statistical test for comparing outcomes","volume":"2","author":"Blevins","year":"1985","journal-title":"MD Comput"},{"key":"10.1016\/j.clinthera.2012.06.014_bib35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jclinepi.2006.09.013","article-title":"Discordance between reported intention-to-treat and per protocol analyses","volume":"60","author":"Porta","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2012.06.014_bib36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2012.06.014_bib37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2012.06.014_bib38","first-page":"249","article-title":"The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2\u2014therapy","volume":"26","author":"Hackam","year":"2010","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.clinthera.2012.06.014_bib39","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.2165\/00003495-200666140-00011","article-title":"Valsartan\/hydrochlorothiazide: a review of its use in the management of hypertension","volume":"66","author":"Wagstaff","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.06.014_bib40","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1586\/erc.09.140","article-title":"Valsartan plus hydrochlorothiazide for first-line therapy in hypertension","volume":"7","author":"Lacourci\u00e8re","year":"2009","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"10.1016\/j.clinthera.2012.06.014_bib41","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1056\/NEJM198909283211305","article-title":"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension","volume":"321","author":"Pollare","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.014_bib42","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1161\/HYPERTENSIONAHA.108.119404","article-title":"Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of candesartan (MEDICA) study","volume":"52","author":"Eriksson","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2012.06.014_bib43","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2169\/internalmedicine.47.1427","article-title":"Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients","volume":"47","author":"Fogari","year":"2008","journal-title":"Intern Med"},{"key":"10.1016\/j.clinthera.2012.06.014_bib44","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/hr.2009.133","article-title":"Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension","volume":"32","author":"Ishimitsu","year":"2009","journal-title":"Hypertens Res"},{"issue":"Suppl 7","key":"10.1016\/j.clinthera.2012.06.014_bib45","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1097\/00005344-198812007-00022","article-title":"Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension","volume":"12","author":"Burris","year":"1988","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.014_bib46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clinthera.2007.02.003","article-title":"Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension","volume":"29","author":"Poldermans","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.06.014_bib47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1185\/03007990903444434","article-title":"Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy","volume":"26","author":"Neutel","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2012.06.014_bib48","first-page":"178","article-title":"Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients","volume":"107","author":"Vijan","year":"2009","journal-title":"J Indian Med Assoc"},{"key":"10.1016\/j.clinthera.2012.06.014_bib49","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812003773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812003773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:48:53Z","timestamp":1758962933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812003773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0149291812003773"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.06.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the Efficacy and Safety Profiles of Two Fixed-Dose Combinations of Antihypertensive Agents, Amlodipine\/Benazepril Versus Valsartan\/Hydrochlorothiazide, in Patients With Type 2 Diabetes Mellitus and Hypertension: A 16-Week, Multicenter, Randomized, Double-Blind, Noninferiority Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}